This segment focuses on the research, development, and clinical trials of small molecule therapeutics for the treatment of Alzheimer's disease. The lead product candidate, ATH-1017 (fosgonimeton), is a key focus, with ongoing Phase II/III LIFT-AD and Phase II ACT-AD clinical trials. Research and development activities include preclinical studies, formulation development, and manufacturing process optimization. The company utilizes advanced methodologies in drug discovery and clinical trial design to evaluate the safety and efficacy of its product candidates. The goal is to provide disease-modifying therapies that can slow or halt the progression of Alzheimer's disease, improving cognitive function and quality of life for patients. Market positioning is based on addressing a significant unmet medical need in a large and growing market. Future opportunities include expanding the clinical development program and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to Good Manufacturing Practices (GMP).

This segment is dedicated to the development of small molecule therapeutics for Parkinson's disease. The company is actively involved in preclinical research and clinical development of product candidates, including ATH-1017, which is being evaluated in clinical trials. Research and development activities include identifying and validating drug targets, synthesizing and characterizing drug candidates, and conducting preclinical and clinical studies. The company employs advanced technologies and methodologies in drug discovery, including high-throughput screening, medicinal chemistry, and clinical trial design. The therapeutic focus is on addressing the motor and non-motor symptoms of Parkinson's disease, with the aim of slowing disease progression and improving patient outcomes. Market positioning is based on addressing a significant unmet medical need in the neurology space. Future opportunities include expanding the clinical development program and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to Good Manufacturing Practices (GMP).

This segment focuses on preclinical research and development of product candidates for neuropsychiatric conditions and peripheral nervous system disorders. This includes ATH-1019/ATH-1020 for neuropsychiatric conditions and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Research and development activities include target identification, drug discovery, preclinical studies, and formulation development. The company utilizes advanced technologies and methodologies in drug discovery, including high-throughput screening, medicinal chemistry, and preclinical models. The therapeutic focus is on addressing unmet medical needs in these areas, with the aim of improving patient outcomes. Market positioning is based on addressing significant unmet medical needs. Future opportunities include advancing product candidates into clinical trials and exploring partnerships. Regulatory and clinical aspects involve navigating regulatory pathways and adhering to Good Manufacturing Practices (GMP).